Daiichi Sankyo's Enhertu Combination Therapy Wins EU Approval for HER2+ Metastatic Breast Cancer
Event summary
- Enhertu (trastuzumab deruxtecan) plus pertuzumab approved in the EU for first-line HER2+ metastatic breast cancer treatment.
- Approval based on DESTINY-Breast09 trial showing 44% reduction in disease progression or death vs. standard therapy.
- Median progression-free survival extended to 40.7 months with Enhertu combo vs. 26.9 months with standard care.
- $100 million milestone payment from AstraZeneca to Daiichi Sankyo triggered by the approval.
The big picture
This approval marks a significant shift in the first-line treatment landscape for HER2+ metastatic breast cancer, an aggressive disease with limited therapeutic progress over the past decade. The Enhertu-pertuzumab combination sets a new benchmark for progression-free survival, potentially reshaping clinical practice and reinforcing Daiichi Sankyo's leadership in antibody-drug conjugate (ADC) technology. The $100 million milestone payment underscores the strategic value of the Daiichi Sankyo-AstraZeneca collaboration in oncology.
What we're watching
- Market Expansion
- Whether Daiichi Sankyo can leverage this approval to accelerate Enhertu's adoption in other major markets.
- Revenue Impact
- The pace at which the new indication will contribute to Daiichi Sankyo's oncology revenue growth.
- Competitive Positioning
- How this approval strengthens Enhertu's lead over competing HER2-targeted therapies in the first-line setting.
Related topics